Page 139

Efficacy of BR as first salvage treatment in CLL

Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015;29(7):1602-1604. 4. Foà R, Guarini A. A mechanism-driven treatment for chronic lymphocytic leukemia? N Engl J Med. 2013;369(1):85-87. 5. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42. 6. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997-1007. 7. Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016;374(4):311-322. 8. Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017;92(9):946-965. 9. Buske C, Hutchings M, Ladetto M, et al. ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. Ann Oncol. 2018;29(3):544562. 10. Wierda WG, Zelenetz AD, Gordon LI, et al. NCCN Guidelines Insights: chronic lymphocytic leukemia/small lymphocytic leukemia, Version 1.2017. J Natl Compr Canc Netw. 2017;15(3):293-311. 11. Green MR, Williams ME, Willey J, Buettner A, Neely D, Lankford M. First-Line Prescribing Preferences of U.S. Hematology-Oncology Physicians for Patients with CLL: Impact of Novel Agents [abstract]. Blood. 2014;124(21):4676. 12. Cramer P, Fink AM, Busch R, et al. Secondline therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group. Leuk Lymphoma. 2013;54(8):1821-1822. 13. Fornecker LM, Aurran-Schleinitz T, Michallet AS, et al. Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience. Am J Hematol. 2015;90(6):511-514. 14. Knauf W, Abenhardt W, Dörfel S, et al. Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms. Hematol Oncol. 2015;33(1):1522.

haematologica | 2018; 103(7)

15. Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29(26):3559-3566. 16. Cortelezzi A, Sciumè M, Liberati AM, et al. Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. Leukemia. 2014;28(3):642-648. 17. Coutré SE, Furman RR, Flinn IW, et al. Extended treatment with single-agent Ibrutinib at the 420 mg dose leads to durable responses in chronic lymphocytic leukemia/small lymphocytic lymphoma. Clin Cancer Res. 2017;23(5):1149-1155. 18. O'Brien SM, Furman RR, Coutre SE, et al. Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. Blood. 2016; 128:233. 19. Brown JR, Hillmen P, O'Brien S, et al. Extended follow-up and impact of highrisk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia. 2018 32(1):83-91. 20. UK CLL Forum. Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients. Haematologica. 2016;101(12):1563-1572. 21. Winqvist M, Asklid A, Andersson PO, et al. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. Haematologica. 2016;101(12):1573-1580. 22. Ghia P, Cuneo A. Ibrutinib in the real world patient: many lights and some shades. Haematologica. 2016;101(12):1448-1450. 23. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111(12):5446-5456. 24. International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLLIPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779-790. 25. Zelenetz AD, Barrientos JC, Brown JR, et al. Idelalisib or placebo in combination

26.

27.

28.

29.

30.

31.

32.

33.

34.

with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017;18(3):297-311. Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17(2):200-211. Follows GA and CLL Forum UK. Outcomes of patients post ibrutinib treatment for relapsed/refractory CLL: a UK and Ireland analysis [abstract]. Hematol Oncol. 2017;35:237-238. Compagno M, Wang Q, Pighi C, et al. Phosphatidylinositol 3-kinase blockade increases genomic instability in B cells. Nature. 2017;542(7642):489-493. Hillmen P, Fraser G, Jones J, et al. Comparing Single-Agent Ibrutinib, Bendamustine Plus Rituximab (BR) and Ibrutinib Plus BR in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): An Indirect Comparison of the RESONATE and HELIOS Trials. Blood. 2015;126(23):2944. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-223. Salles GA, Baseggio L, Bachy E, et al. Single-Agent Ibrutinib Vs Standard of Care for Patients with Relapsed/Refractory (R/R) and Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): An Adjusted Comparison of RESONATETM and RESONATE-2TM with the French Lyon-Sud Database. Blood. 2016;128(22):2039. Hansson L, Asklid A, Diels J, et al. Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia. Ann Hematol. 2017; 96(10):1681-1691. Mato AR, Lamanna N, Ujjani CS, et al. Toxicities and Outcomes of IbrutinibTreated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients. Blood. 2016;128(22):3222. Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from PrePlanned Interim Analysis of the Randomized Phase 3 Murano Study [abstract]. Blood. 2017;130(Suppl 1):LBA-2.

1217

Haematologica, Volume 103, Issue 7  
Haematologica, Volume 103, Issue 7